tbResList Print — CET cetuximab

Filters: qv=5, qv2=%, rfv=%

Product

CET cetuximab
Features: antineoplastic drug
Description: <b>Cetuximab</b> a genetically engineered monoclonal antibody (IV): inhibit tumor growth for colorectal cancer, head and neck cancer. <br>
Cardiopulmonary arrest side effect. <br>

Pathway results for Effect on Cancer / Diseased Cells

Redox & Oxidative Stress ⓘ

Ferroptosis↓, 1,   GSH↓, 1,   MDA↑, 1,   ROS↑, 1,   xCT↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,  

Core Metabolism/Glycolysis ⓘ

HK2↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   Ferroptosis↓, 1,  

Kinase & Signal Transduction ⓘ

AMPKα↑, 1,  

Autophagy & Lysosomes ⓘ

p‑Beclin-1↑, 1,   TumAuto↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

FOXO3↑, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 1,   eff↑, 1,   eff↓, 1,  

Functional Outcomes ⓘ

TumVol↓, 1,   TumW↓, 1,  
Total Targets: 18

Pathway results for Effect on Normal Cells

Total Targets: 0

Research papers

Year Title Authors PMID Link Flag
20233-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosisMingchao Mu—https://www.nature.com/articles/s41417-023-00648-50